News Release

New Year Greeting

• Ranked in the Financial Times, “High-Growth Companies Asia-Pacific 2021” for the second consecutive year
• Chinese Journal of Tuberculosis and Respiratory Diseases recommended the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China